Moderna (MRNA) PT Raised to $179 at Oppenheimer, 'mResvia is competitive as an RSV vaccine'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Moderna (MRNA) PT Raised to $179 at Oppenheimer, 'mResvia is competitive as an RSV vaccine'

Moderna (MRNA) price target raised at Oppenheimer after RSV vaccine approval

June 12, 2024 7:45 AM EDT

Oppenheimer upped their price target on Moderna (NASDAQ: MRNA) after the US drugmaker recently saw its respiratory syncytial virus (RSV) vaccine, known as mRESVIA, approved by the Food and Drug Administration (FDA).

According to Oppenheimer, mResvia is entering the adult market (ages 60 and above), where it will... More